Evaluation of Brain Perfusion with Radionuclide Imaging in Dementia Patients
Article Sidebar
Main Article Content
Abstract
Objective: This study aims to evaluate the perfusion in the affected brain lobes with radionuclide imaging in patients with dementia and to contribute to the literature by determining the relationship between the degree of dementia.
Methods: In this retrospective study, 44 adult patients were included. The mean age of the patients was 73 (57-87). Twenty-three (52.3%) of these were female. All patients underwent mini-mental state test, neurological examinations and radionuclide brain perfusion imaging. The areas of interest of the frontal, parietal, temporal, and occipital lobes and the cerebellum were drawn, respectively, and the cerebellum ratios of the relevant lobes were compared. In this way, brain perfusion index values of lobes were obtained.
Results: Brain perfusion in group 1 was higher than in other groups. Groups were also compared in pairs. There was no significant difference in perfusion values in the occipital lobe. There was a significant difference in perfusion between groups 1 and 2 in lobes other than the occipital lobe. This was also the case for Groups 1 and 3. When group 2 with early dementia symptoms, and group 3 with moderate dementia were compared, there was a significant difference between the perfusion values of only the right and left frontal lobes.
Conclusion: Early diagnosis is very important in progressive dementia. Clinical tests are successfully applied to categorize patients. Evaluation of brain perfusion and metabolism with functional radionuclide imaging is significant in guiding the treatment and evaluating the success of the treatment.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Accepted 2023-08-22
Published 2023-08-24
References
Folstein MF, Basset SS, Anthony JC, Romanoski AJ, Nestadt GR. Dementia: case ascertainment in a community survey. J Gerontol. 1991;46:132-8.
Bird TD, Miller BL. Alzheimer's disease and other dementias. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, editors. Harrison’s Principles of Internal Medicine. 16th Edition. New York: McGraw-Hill Companies; 2005. pp. 2393-2406.
Nagren K, Haldin C, Rinne JO. Radiopharmaceuticals for positron emission tomography investigations of Alzheimer’s disease. Eur J Med Mol Imaging. 2009;22:22-30.
Guerra UP. Brain SPECT; A Normal Brain Morpho-Functional Atlas.
Hafkemeijer A, van der Grond J, Rombouts SA. Imaging the default mode network in aging and dementia. Biochim Biophys Acta. 2012;1822:431-41.
Trzepacz PT, Yu P, Sun J, et al. Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer’s dementia. Neurobiol Aging. 2014;35:143-51.
Diehl-Schmid J, Onur OA, Kuhn J, Gruppe T, Drzezga A. Imaging frontotemporal lobar degeneration. Curr Neurol Neurosci Rep. 2014;14:489.
Bonifacio G, Zamboni G. Brain imaging in dementia. Postgrad Med J. 2016;92:333-40.
Hampel H, Burger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K. Core candidate neurochemical and imaging biomarkers of Alzheimer’s disease. Alzheimers Dement. 2008;4:38-48.
Murray AD. Imaging approaches for dementia. AJNR Am J Neuroradiol. 2011;33:1836-44.
Brundel M, Kwa VI, Bouvy WH, Algra A, Kappelle LJ, Biessels GJ. Cerebral microbleeds are not associated with long-term cognitive outcomes in patients with transient ischemic attack or minor stroke. Cerebrovasc Dis. 2014;37:195-202.
O’Brien JT, Firbank MJ, Davison C, et al. 18F-FDG PET and perfusion SPECT in the diagnosis of Alzheimer and Lewy body dementias. J Nucl Med. 2014;55(12):1959-65.
Frisoni GB, Bocchetta M, Chételat G, et al. Imaging markers for Alzheimer's disease: which vs how. Neurology. 2013;81(5):487-500.
Yeo JM, Lim X, Khan Z, et al. A systematic review of the diagnostic utility of SPECT in dementia. Eur Arch Psychiatry Clin Neurosci 2013;263(7):539e52.
Kadir A, Nordberg A. Target-specific PET probes for neurodegenerative disorders related to dementia. J Nucl Med. 2010;51:1418–30.
National Institute for Health and Care Excellence. Dementia: assessment, management, and support for people living with dementia and their carers. NICE guideline 97 [NG97]. London. 2018.
Bradley KM, O’Sullivan VT, Soper ND. Cerebral Perfusion SPET Correlated with Braak Pathological Stage in Alzheimer’s Disease. Brain. 2002;125(8):1772-1781.
Olazaran J, Alvarez-Linera J, de Santiago R. Regional Correlations between MR Imaging Perfusion and SPECT in Alzheimer’s Disease. Neurologia. 2005;20:240-244.
McMurdo ME, Grant DJ, Kennedy NSJ, Gilchrist J, Findlay D, McLeman JM. The Value of HMPAO SPECT Scanning in the Diagnosis of Early Alzheimer’s Disease in Patients Attending A Memory Clinic. Nucl Med Commun. 1994;15:405-409.
Bird TD, Miller BL. Alzheimer's disease and other dementias. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, editors. Harrison’s Principles of Internal Medicine. 16th Edition. New York: McGraw-Hill Companies; 2005. pp. 2393-2406.
Prunier C, Payoux P, Guilloteau D, Chalon S, Giraudeau B, Majorel C, Tafaui M, Bezard E, Esquerre JP, Baulieu JL. Quantification of dopamine transporter by 123 I-PE21 SPECT and noninvasive Logan graphical method in Parkinson’s disease. J Nucl Med. 2003 May;44(5):663-70.
Delacourte A, David JP, Sergeant N, Buée L, Wattez A, Vermersch P. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer’s disease. Neurol. 1999;52:1158-1165.
Bosco P, Redolfi A, Bocchetta M, et al. The impact of automated hippocampal volumetry on diagnostic confidence in patients with suspected Alzheimer’s disease: a European Alzheimer’s Disease Consortium study. Alzheimer’s Dement. 2017;13(9):1013-23.
Breteler MMB. Mapping out biomarkers for Alzheimer’s disease. JAMA. 2011;305:304–5.